Anti-SARS-CoV-1, Spike (Clone COV1-100) -Purified No Carrier Protein

Specificity: COV1-100 targets the prefusion spike protein (S2) of SARS-CoV-1 and SARS-CoV- 2. Antigen Distribution: Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells. Background: SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. The COV1-100 monoclonal antibody targets the spike protein of both SARS-CoV-1 and SARS- CoV-2, demonstrating cross-reactivity. However, it does not block the ACE2 receptor and does not function as a neutralizer. The epitope targeted by COV1-100 is unknown, which indicates that more research is needed to determine its binding site and potential role in viral inhibition. Despite not being a neutralizer, COV1-100 might play a role in modulating the immune response or could be useful in combination with other antibodies that have neutralizing capabilities, providing a broader spectrum of antiviral activity.